Global Antibody Drug Conjugates (ADCs) Market Size, Status and Forecast 2024-2031

Report ID: 954939 | Published Date: Jan 2025 | No. of Page: 109 | Base Year: 2024 | Rating: 4.1 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Seattle Genetics Technology
        1.2.3 ImmunoGen Technology
        1.2.4 Immunomedics Technology
    1.3 Market by Application
        1.3.1 Global Antibody Drug Conjugates (ADCs) Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital
        1.3.3 Clinics
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Antibody Drug Conjugates (ADCs) Market Perspective (2016-2027)
    2.2 Antibody Drug Conjugates (ADCs) Growth Trends by Regions
        2.2.1 Antibody Drug Conjugates (ADCs) Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Antibody Drug Conjugates (ADCs) Historic Market Share by Regions (2016-2021)
        2.2.3 Antibody Drug Conjugates (ADCs) Forecasted Market Size by Regions (2022-2027)
    2.3 Antibody Drug Conjugates (ADCs) Industry Dynamic
        2.3.1 Antibody Drug Conjugates (ADCs) Market Trends
        2.3.2 Antibody Drug Conjugates (ADCs) Market Drivers
        2.3.3 Antibody Drug Conjugates (ADCs) Market Challenges
        2.3.4 Antibody Drug Conjugates (ADCs) Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Antibody Drug Conjugates (ADCs) Players by Revenue
        3.1.1 Global Top Antibody Drug Conjugates (ADCs) Players by Revenue (2016-2021)
        3.1.2 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Players (2016-2021)
    3.2 Global Antibody Drug Conjugates (ADCs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Antibody Drug Conjugates (ADCs) Revenue
    3.4 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio
        3.4.1 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugates (ADCs) Revenue in 2020
    3.5 Antibody Drug Conjugates (ADCs) Key Players Head office and Area Served
    3.6 Key Players Antibody Drug Conjugates (ADCs) Product Solution and Service
    3.7 Date of Enter into Antibody Drug Conjugates (ADCs) Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody Drug Conjugates (ADCs) Breakdown Data by Type
    4.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Type (2016-2021)
    4.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Type (2022-2027)

5 Antibody Drug Conjugates (ADCs) Breakdown Data by Application
    5.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Application (2016-2021)
    5.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Antibody Drug Conjugates (ADCs) Market Size (2016-2027)
    6.2 North America Antibody Drug Conjugates (ADCs) Market Size by Type
        6.2.1 North America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021)
        6.2.2 North America Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027)
        6.2.3 North America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2027)
    6.3 North America Antibody Drug Conjugates (ADCs) Market Size by Application
        6.3.1 North America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021)
        6.3.2 North America Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027)
        6.3.3 North America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2027)
    6.4 North America Antibody Drug Conjugates (ADCs) Market Size by Country
        6.4.1 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021)
        6.4.2 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Antibody Drug Conjugates (ADCs) Market Size (2016-2027)
    7.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Type
        7.2.1 Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021)
        7.2.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027)
        7.2.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2027)
    7.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Application
        7.3.1 Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021)
        7.3.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027)
        7.3.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2027)
    7.4 Europe Antibody Drug Conjugates (ADCs) Market Size by Country
        7.4.1 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021)
        7.4.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size (2016-2027)
    8.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type
        8.2.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2027)
    8.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application
        8.3.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2027)
    8.4 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region
        8.4.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Antibody Drug Conjugates (ADCs) Market Size (2016-2027)
    9.2 Latin America Antibody Drug Conjugates (ADCs) Market Size by Type
        9.2.1 Latin America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021)
        9.2.2 Latin America Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027)
        9.2.3 Latin America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2027)
    9.3 Latin America Antibody Drug Conjugates (ADCs) Market Size by Application
        9.3.1 Latin America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021)
        9.3.2 Latin America Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027)
        9.3.3 Latin America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2027)
    9.4 Latin America Antibody Drug Conjugates (ADCs) Market Size by Country
        9.4.1 Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021)
        9.4.2 Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size (2016-2027)
    10.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type
        10.2.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2027)
    10.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application
        10.3.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2027)
    10.4 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country
        10.4.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Roche
        11.1.1 Roche Company Details
        11.1.2 Roche Business Overview
        11.1.3 Roche Antibody Drug Conjugates (ADCs) Introduction
        11.1.4 Roche Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.1.5 Roche Recent Development
    11.2 Pfizer
        11.2.1 Pfizer Company Details
        11.2.2 Pfizer Business Overview
        11.2.3 Pfizer Antibody Drug Conjugates (ADCs) Introduction
        11.2.4 Pfizer Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.2.5 Pfizer Recent Development
    11.3 Novartis
        11.3.1 Novartis Company Details
        11.3.2 Novartis Business Overview
        11.3.3 Novartis Antibody Drug Conjugates (ADCs) Introduction
        11.3.4 Novartis Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.3.5 Novartis Recent Development
    11.4 Genmab
        11.4.1 Genmab Company Details
        11.4.2 Genmab Business Overview
        11.4.3 Genmab Antibody Drug Conjugates (ADCs) Introduction
        11.4.4 Genmab Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.4.5 Genmab Recent Development
    11.5 Bayer
        11.5.1 Bayer Company Details
        11.5.2 Bayer Business Overview
        11.5.3 Bayer Antibody Drug Conjugates (ADCs) Introduction
        11.5.4 Bayer Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.5.5 Bayer Recent Development
    11.6 Seattle Genetics
        11.6.1 Seattle Genetics Company Details
        11.6.2 Seattle Genetics Business Overview
        11.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Introduction
        11.6.4 Seattle Genetics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.6.5 Seattle Genetics Recent Development
    11.7 Takeda Pharmaceuticals
        11.7.1 Takeda Pharmaceuticals Company Details
        11.7.2 Takeda Pharmaceuticals Business Overview
        11.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Introduction
        11.7.4 Takeda Pharmaceuticals Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.7.5 Takeda Pharmaceuticals Recent Development
    11.8 AbbVie
        11.8.1 AbbVie Company Details
        11.8.2 AbbVie Business Overview
        11.8.3 AbbVie Antibody Drug Conjugates (ADCs) Introduction
        11.8.4 AbbVie Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.8.5 AbbVie Recent Development
    11.9 AbGenomics
        11.9.1 AbGenomics Company Details
        11.9.2 AbGenomics Business Overview
        11.9.3 AbGenomics Antibody Drug Conjugates (ADCs) Introduction
        11.9.4 AbGenomics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.9.5 AbGenomics Recent Development
    11.10 ADC Therapeutics
        11.10.1 ADC Therapeutics Company Details
        11.10.2 ADC Therapeutics Business Overview
        11.10.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Introduction
        11.10.4 ADC Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.10.5 ADC Therapeutics Recent Development
    11.11 Astellas Pharma
        11.11.1 Astellas Pharma Company Details
        11.11.2 Astellas Pharma Business Overview
        11.11.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Introduction
        11.11.4 Astellas Pharma Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.11.5 Astellas Pharma Recent Development
    11.12 Kairos Therapeutics
        11.12.1 Kairos Therapeutics Company Details
        11.12.2 Kairos Therapeutics Business Overview
        11.12.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Introduction
        11.12.4 Kairos Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
        11.12.5 Kairos Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Seattle Genetics Technology
    Table 3. Key Players of ImmunoGen Technology
    Table 4. Key Players of Immunomedics Technology
    Table 5. Global Antibody Drug Conjugates (ADCs) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Antibody Drug Conjugates (ADCs) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Antibody Drug Conjugates (ADCs) Market Size by Regions (2016-2021) & (US$ Million)
    Table 8. Global Antibody Drug Conjugates (ADCs) Market Share by Regions (2016-2021)
    Table 9. Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 10. Global Antibody Drug Conjugates (ADCs) Market Share by Regions (2022-2027)
    Table 11. Antibody Drug Conjugates (ADCs) Market Trends
    Table 12. Antibody Drug Conjugates (ADCs) Market Drivers
    Table 13. Antibody Drug Conjugates (ADCs) Market Challenges
    Table 14. Antibody Drug Conjugates (ADCs) Market Restraints
    Table 15. Global Antibody Drug Conjugates (ADCs) Revenue by Players (2016-2021) & (US$ Million)
    Table 16. Global Antibody Drug Conjugates (ADCs) Market Share by Players (2016-2021)
    Table 17. Global Top Antibody Drug Conjugates (ADCs) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugates (ADCs) as of 2020)
    Table 18. Ranking of Global Top Antibody Drug Conjugates (ADCs) Companies by Revenue (US$ Million) in 2020
    Table 19. Global 5 Largest Players Market Share by Antibody Drug Conjugates (ADCs) Revenue (CR5 and HHI) & (2016-2021)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Antibody Drug Conjugates (ADCs) Product Solution and Service
    Table 22. Date of Enter into Antibody Drug Conjugates (ADCs) Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
    Table 25. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2016-2021)
    Table 26. Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 27. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 28. Global Antibody Drug Conjugates (ADCs) Market Size Share by Application (2016-2021) & (US$ Million)
    Table 29. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2016-2021)
    Table 30. Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 31. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 32. North America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
    Table 33. North America Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027) & (US$ Million)
    Table 34. North America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021) (US$ Million)
    Table 35. North America Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027) & (US$ Million)
    Table 36. North America Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021) & (US$ Million) 
    Table 37. North America Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027) & (US$ Million) 
    Table 38. Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
    Table 39. Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027) & (US$ Million)
    Table 40. Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021) (US$ Million)
    Table 41. Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027) & (US$ Million)
    Table 42. Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021) & (US$ Million) 
    Table 43. Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027) & (US$ Million) 
    Table 44. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
    Table 45. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027) & (US$ Million)
    Table 46. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2016-2021) & (US$ Million) 
    Table 49. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2022-2027) & (US$ Million) 
    Table 50. Latin America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
    Table 51. Latin America Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027) & (US$ Million)
    Table 52. Latin America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021) (US$ Million)
    Table 53. Latin America Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027) & (US$ Million)
    Table 54. Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021) & (US$ Million) 
    Table 55. Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027) & (US$ Million) 
    Table 56. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
    Table 57. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027) & (US$ Million)
    Table 58. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021) & (US$ Million) 
    Table 61. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027) & (US$ Million) 
    Table 62. Roche Company Details
    Table 63. Roche Business Overview
    Table 64. Roche Antibody Drug Conjugates (ADCs) Product
    Table 65. Roche Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 66. Roche Recent Development
    Table 67. Pfizer Company Details
    Table 68. Pfizer Business Overview
    Table 69. Pfizer Antibody Drug Conjugates (ADCs) Product
    Table 70. Pfizer Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 71. Pfizer Recent Development
    Table 72. Novartis Company Details
    Table 73. Novartis Business Overview
    Table 74. Novartis Antibody Drug Conjugates (ADCs) Product
    Table 75. Novartis Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 76. Novartis Recent Development
    Table 77. Genmab Company Details
    Table 78. Genmab Business Overview
    Table 79. Genmab Antibody Drug Conjugates (ADCs) Product
    Table 80. Genmab Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 81. Genmab Recent Development
    Table 82. Bayer Company Details
    Table 83. Bayer Business Overview
    Table 84. Bayer Antibody Drug Conjugates (ADCs) Product
    Table 85. Bayer Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 86. Bayer Recent Development
    Table 87. Seattle Genetics Company Details
    Table 88. Seattle Genetics Business Overview
    Table 89. Seattle Genetics Antibody Drug Conjugates (ADCs) Product
    Table 90. Seattle Genetics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 91. Seattle Genetics Recent Development
    Table 92. Takeda Pharmaceuticals Company Details
    Table 93. Takeda Pharmaceuticals Business Overview
    Table 94. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product
    Table 95. Takeda Pharmaceuticals Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 96. Takeda Pharmaceuticals Recent Development
    Table 97. AbbVie Company Details
    Table 98. AbbVie Business Overview
    Table 99. AbbVie Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 100. AbbVie Recent Development
    Table 101. AbGenomics Company Details
    Table 102. AbGenomics Business Overview
    Table 103. AbGenomics Antibody Drug Conjugates (ADCs) Product
    Table 104. AbGenomics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 105. AbGenomics Recent Development
    Table 106. ADC Therapeutics Company Details
    Table 107. ADC Therapeutics Business Overview
    Table 108. ADC Therapeutics Antibody Drug Conjugates (ADCs) Product
    Table 109. ADC Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 110. ADC Therapeutics Recent Development
    Table 111. Astellas Pharma Company Details
    Table 112. Astellas Pharma Business Overview
    Table 113. Astellas Pharma Antibody Drug Conjugates (ADCs) Product
    Table 114. Astellas Pharma Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 115. Astellas Pharma Recent Development
    Table 116. Kairos Therapeutics Company Details
    Table 117. Kairos Therapeutics Business Overview
    Table 118. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product
    Table 119. Kairos Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
    Table 120. Kairos Therapeutics Recent Development
    Table 121. Research Programs/Design for This Report
    Table 122. Key Data Information from Secondary Sources
    Table 123. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Antibody Drug Conjugates (ADCs) Market Share by Type: 2020 VS 2027
    Figure 2. Seattle Genetics Technology Features
    Figure 3. ImmunoGen Technology Features
    Figure 4. Immunomedics Technology Features
    Figure 5. Global Antibody Drug Conjugates (ADCs) Market Share by Application: 2020 VS 2027
    Figure 6. Hospital Case Studies
    Figure 7. Clinics Case Studies
    Figure 8. Others Case Studies
    Figure 9. Antibody Drug Conjugates (ADCs) Report Years Considered
    Figure 10. Global Antibody Drug Conjugates (ADCs) Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 11. Global Antibody Drug Conjugates (ADCs) Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 12. Global Antibody Drug Conjugates (ADCs) Market Share by Regions: 2020 VS 2027
    Figure 13. Global Antibody Drug Conjugates (ADCs) Market Share by Regions (2022-2027)
    Figure 14. Global Antibody Drug Conjugates (ADCs) Market Share by Players in 2020
    Figure 15. Global Top Antibody Drug Conjugates (ADCs) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugates (ADCs) as of 2020
    Figure 16. The Top 10 and 5 Players Market Share by Antibody Drug Conjugates (ADCs) Revenue in 2020
    Figure 17. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2016-2021)
    Figure 18. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2022-2027)
    Figure 19. North America Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 20. North America Antibody Drug Conjugates (ADCs) Market Share by Type (2016-2027)
    Figure 21. North America Antibody Drug Conjugates (ADCs) Market Share by Application (2016-2027)
    Figure 22. North America Antibody Drug Conjugates (ADCs) Market Share by Country (2016-2027)
    Figure 23. United States Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Canada Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Antibody Drug Conjugates (ADCs) Market Share by Type (2016-2027)
    Figure 27. Europe Antibody Drug Conjugates (ADCs) Market Share by Application (2016-2027)
    Figure 28. Europe Antibody Drug Conjugates (ADCs) Market Share by Country (2016-2027)
    Figure 29. Germany Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. France Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. U.K. Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Italy Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Russia Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Nordic Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Share by Type (2016-2027)
    Figure 37. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Share by Application (2016-2027)
    Figure 38. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Share by Region (2016-2027)
    Figure 39. China Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Japan Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. South Korea Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Southeast Asia Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. India Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Australia Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Antibody Drug Conjugates (ADCs) Market Share by Type (2016-2027)
    Figure 47. Latin America Antibody Drug Conjugates (ADCs) Market Share by Application (2016-2027)
    Figure 48. Latin America Antibody Drug Conjugates (ADCs) Market Share by Country (2016-2027)
    Figure 49. Mexico Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Brazil Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Type (2016-2027)
    Figure 53. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Application (2016-2027)
    Figure 54. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Country (2016-2027)
    Figure 55. Turkey Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Saudi Arabia Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. UAE Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Roche Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 59. Pfizer Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 60. Novartis Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 61. Genmab Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 62. Bayer Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 63. Seattle Genetics Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 64. Takeda Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 65. AbbVie Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 66. AbGenomics Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 67. ADC Therapeutics Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 68. Astellas Pharma Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 69. Kairos Therapeutics Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
    Figure 70. Bottom-up and Top-down Approaches for This Report
    Figure 71. Data Triangulation
    Figure 72. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Astellas Pharma
Kairos Therapeutics
Frequently Asked Questions
Antibody Drug Conjugates (ADCs) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Antibody Drug Conjugates (ADCs) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Antibody Drug Conjugates (ADCs) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

AR Gaming

Mobile device manufacturers recently started integrating AR technology into their devices to offe ... Read More